Testimonials
Customers
"Proveris Scientific Corporation provides expert support for nasal developers. They are fast, reliable and personal initiative at installation of their equipment as at latter support in demanding challenges."
- Peter Svete, PhD, Head Physical Analytics, Lek Pharmaceuticals d.d.
"Proveris provides insightful and thorough test services. We would recommend working with Proveris. Proveris has great expertise in spray analysis."
- Elaine Schutte, Chief Development Officer, ProFibrix
Literature
"The SprayVIEWTM NSx system permits a versatile range of settings for stroke length, hold time, IAD time, ctuation/return stroke velocity, and acceleration. It also monitors and records the actual force and displacement profiles for later analysis.
...
The SprayVIEWTM NSP software automatically determines the contour of the spray pattern and reports all the spray pattern measurements recommended by the FDA including Dmax, Dmin, ovality, area, and center of mass (COM).
...
The small standard deviations observed for these measurement results indicate that the SprayVIEWTM NSx automated actuation station is capable of delivering reproducible actuation performance thus facilitating the measurement of various nasal spray characteristics."
- The Influence of Actuation Parameters on In Vitro Testing of Nasal Spray Products.
Guo C,
Doub WH.
Corresponding author: changning.guo@fda.hhs.gov
Division of Pharmaceutical Analysis, U. S. Food and Drug Administration, 1114 Market Street, Room 1002, St. Louis, Missouri 63101
"Optimization of actuation parameters for each nasal spray and MDI product was performed using the SprayVIEW NSx/MDx automated actuators. The relative standard deviation (RSD) for six replicates measurements of impaction force varied from 2.1% to 6.6% for all tested products, indicating good repeatability for the method.
-Evaluation of impaction force of nasal sprays and metered-dose inhalers using the Texture Analyser
Guo C,
Ye W,
Kauffman JF,
Doub WH.
Corresponding author: changning.guo@fda.hhs.gov
U.S. Food & Drug Administration, Division of Pharmaceutical Analysis, 1114 Market Street, Room 1002,
St. Louis, Missouri 63101